ANGPTL4

DGAP-News: First subject dosed in Lipigon’s phase I clinical study with antisense oligonucleotide candidate derived from Secarna Pharmaceutical’s LNAplus™ technology platform

Retrieved on: 
Tuesday, May 31, 2022
Company, Hypertriglyceridemia, FCS, ASO, Lipid metabolism, Patient, Lipid, Liver, ANGPTL4, Trial of the century, Efficiency, Industry, Plasma, Asos, RNA, Evotec, Medical Products Agency (Sweden), Drug discovery, LNA, Achievement, CEO, Fine chemical, Pharmaceutical industry, Angiopoietin

Lipisense is an antisense oligonucleotide (ASO) discovered and developed with Secarnas proprietary LNAplus platform for the treatment of rare lipid-related-diseases.

Key Points: 
  • Lipisense is an antisense oligonucleotide (ASO) discovered and developed with Secarnas proprietary LNAplus platform for the treatment of rare lipid-related-diseases.
  • The Swedish Medical Products Agency approved the trial last week and the first subject has already been dosed.
  • Progression of the drug candidate into the clinic triggered an undisclosed milestone payment to Secarna.
  • This is a major milestone for Secarna as well because Lipisense is the first ASO derived from our LNAplus technology platform which has progressed into clinical development.

DGAP-News: Antisense oligonucleotide candidate derived from Secarna Pharmaceuticals' LNAplusTM platform has entered pre-clinical safety trials for the treatment of elevated blood lipids

Retrieved on: 
Tuesday, January 19, 2021
Branches of biology, Biology, ANGPTL4, Molecular biology, RNA, Molecules, Sense, Lipid metabolism, Triglyceride, Oligonucleotide, Custirsen, Secarna's proprietary drug discovery platform, LNAplusTM, Secarna Pharmaceuticals GmbH & Co. KG, Lipigon Pharmaceuticals

Lipisense, an antisense oligonucleotide (ASO) which has been developed with Secarna's proprietary LNAplusTM platform, is a first-in-class treatment with a novel mechanism of action central for the regulation of plasma triglycerides and other plasma lipids.

Key Points: 
  • Lipisense, an antisense oligonucleotide (ASO) which has been developed with Secarna's proprietary LNAplusTM platform, is a first-in-class treatment with a novel mechanism of action central for the regulation of plasma triglycerides and other plasma lipids.
  • The drug candidate hinders the cellular production of ANGPTL4, a protein that has a direct role in lipid metabolism by blocking the clearance of triglycerides.
  • The LNAplusTM ASO-based drug candidate has shown strong efficacy in experimental disease models and a good safety profile in preliminary safety studies.
  • About Secarna's proprietary drug discovery platform, LNAplusTM
    For discovering, testing and selecting antisense oligonucleotides (ASOs) for pre-clinical and clinical development, Secarna employs its proprietary, customized LNAplusTM drug discovery platform.

DGAP-News: Secarna Pharmaceuticals announces the acquisition of LNAplusTM based antisense drug candidates by Lipigon Pharmaceuticals

Retrieved on: 
Monday, March 23, 2020
Branches of biology, Biology, Life sciences, Applied genetics, Therapeutic gene modulation, Antisense therapy, Biotechnology, Gene therapy, RNA, ANGPTL4, Sense, Oligonucleotide, Secarna's proprietary drug discovery platform, LNAplus, Secarna Pharmaceuticals GmbH & Co. KG, Lipigon Pharmaceuticals

Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.

Key Points: 
  • Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.
  • The antisense oligonucleotide candidates targeting the ANGPTL gene family for the treatment of cardiovascular and metabolic diseases were previously generated by Secarna and Lipigon under a target validation and drug discovery collaboration.
  • Going forward, Lipigon will fund and continue the development of the acquired assets and Secarna receives payments customary for such a transaction.
  • Inhibiting the ANGPTL gene family members ANGPTL3 and ANGPTL4 with Secarna's LNAplusTM based antisense oligonucleotides has shown to positively affect plasma lipid levels.